Résumé
ABSTRACT Ligneous conjunctivitis is a rare form of chronic and recurrent bilateral conjunctivitis, in which thick membranes develop on the tarsal conjunctiva and on other mucosae. We report the case of a 55-year old female patient with bilateral ligneous conjunctivitis who was successfully treated with 50% heterologous serum. There was no recurrence or side effects after one-year follow-up. We suggest the use of 50% heterologous serum should be further studied to better determine its efficacy as a treatment option for ligneous conjunctivitis.
RESUMO A conjuntivite lenhosa é uma forma rara de conjuntivite bilateral crônica e recorrente, na qual há formação de membranas espessas na conjuntiva tarsal e em outras mucosas. Relatamos o caso de uma paciente de 55 anos com conjuntivite lenhosa bilateral, que obteve sucesso no tratamento com soro heterólogo em concentração de 50%. Não houve recorrência após um ano de seguimento e nem efeitos colaterais ao tratamento. Dessa forma, o uso de soro heterólogo a 50% poderia ser mais estudado para melhor avaliação de sua eficácia como opção de tratamento para a conjuntivite lenhosa.
Sujets)
Humains , Femelle , Plasminogène/déficit , Sérum , Plasminogène/usage thérapeutique , Maladies génétiques de la peau/anatomopathologie , Résultat thérapeutique , Conjonctivite/anatomopathologie , Adulte d'âge moyenRésumé
The study of the National Institute of Neurological Disorders and Stroke (NINDS) proved that the use of the recombinant tissue plasminogen activator (rtPA) within the first 3 hours since the beginning of the symptomatology of the acute ischemis stroke (AIS) is as well safe as effective...These preliminary data reported in our study show that a strict protocol of thrombolysis IV with rtPA in AIS is feasible to be carried on with good results in a high complexity Center.
Sujets)
Humains , Sujet âgé , Accident ischémique transitoire/anatomopathologie , Accident ischémique transitoire/thérapie , Tests de coagulation sanguine , Pompes à perfusion , Plasminogène/administration et posologie , Plasminogène/usage thérapeutique , Traitement thrombolytique , Tomodensitométrie , Numération des plaquettesRésumé
Recent studies have shown the possibility to treat cancer with drugs that affect the formation of new blood vessels instead of attacking directly the malignant cell. This relatively new field in the area of oncology on angiogenesis inhibition has expanded the therapeutic option for malignant diseases. We will discuss several antiangiogenesis drugs in clinical development and their mechanism of action. Some of these drugs include: angiostatin, metalloproteinase inhibitors, thalidomide, tamoxifen, interferons and others. The use of antiangiogenic agents, both in combination with other treatment modalities in the acute setting as well as long-term maintenance or prevention of cancer, is at present one of the better promises in the war against cancer.
Sujets)
Humains , Inhibiteurs de l'angiogenèse/usage thérapeutique , Tumeurs/vascularisation , Néovascularisation pathologique/traitement médicamenteux , Essais cliniques comme sujet , Collagène/usage thérapeutique , Fragments peptidiques/usage thérapeutique , Plasminogène/usage thérapeutiqueRésumé
PURPOSE--To relate our experience with thrombolytic therapy in 8 patients with cardiac metal prosthesis complicated with thrombosis. METHODS--Eight patients with clinical and echocardiographic diagnosis of cardiac valvar prosthesis thrombosis were treated. RESULTS--The treatment efficacy was evaluated by clinical and echocardiographic improvement. The authors recognized improvement in all 8 patients. One case of hemorrhage was observed (coxo-femoral articulation). Late death were observed twice: 24 months after, sudden death and 30 months later by hemorrhagic stroke. CONCLUSION--The results indicated that thrombolytic therapy is best way to treat patients with cardiac valve thrombosis, instead of surgical treatment